Chronic Obstructive Pulmonary Disease – Epidemiology – Middle East & Africa
DRG Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of COPD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
DRG Epidemiology’s COPD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with COPD?
In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of COPD?
Of all people with COPD, how many in each country have been formally diagnosed?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of COPD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following COPD subpopulations:
ACOS.
Eosinophilic COPD.
Severity status.
Drug-treatment status.
Exacerbations in mild-moderate disease status.
Exacerbations in severe-very severe disease status.
Chronic Obstructive Pulmonary Disease - Epidemiology - Middle East & Africa
Introduction
Total Prevalence of Chronic Obstructive Pulmonary Disease per 100 People Aged 40 or Older in 2021 and 2031
Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Chronic Obstructive Pulmonary Disease Over the Next 10 Years
Analysis of Total Prevalent Cases of Chronic Obstructive Pulmonary Disease in 2021 by Diagnosis Status
Analysis of the GOLD-Defined Prevalent Cases of Chronic Obstructive Pulmonary Disease in 2021 by Disease Severity
Epidemiology Data
Methods
Total GOLD-Defined Prevalent Cases
Total Prevalent Cases
Spirometric-Negative Prevalent Cases
Total GOLD-Defined Prevalent Cases by Severity
Diagnosed GOLD-Defined Prevalent Cases
Diagnosed Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Chronic Obstructive Pulmonary Disease
Studies Excluded from the Analysis of Chronic Obstructive Pulmonary Disease
Risk/Protective Factors
Risk/Protective Factors for Chronic Obstructive Pulmonary Disease
Bibliography
Abbreviations
Glossary
Navya Vardhan
Navya Vardhan, M.Sc., is an associate epidemiologist at Clarivate. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.
Stephanie Niquita Phankon
Stephanie Niquita Phankon, M.B.B.S., M.P.H., is a senior epidemiologist at Clarivate. She trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects. She holds an M.P.H. specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China.
